EUVIMEDEUVIMED entdecken
Crossref

Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling

Nicole Kabella iD, Florian P Bayer iD, Konstantinos Stamatiou iD, Miriam Abele iD, Amirhossein Sakhteman iD, Yun-Chien Chang iD, Vinona Wagner, Antje Gabriel iD, Johannes Krumm iD, Maria Reinecke, Melanie Holzner, Michael Aigner iD und 6 weitere

Science Signaling · 29.07.2025 · 18 (897)

DOI: 10.1126/scisignal.adt6552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, erschienen am 29.07.2025. Verfasst von Nicole Kabella und 17 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Technical University of Munich, Freising, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Proteomics, Signal Transduction, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations that activate the small GTPase KRAS are a frequent genetic alteration in cancer, and drug discovery efforts have led to inhibitors that block KRAS activity. We sought to better understand oncogenic KRAS signaling and the cytostatic effects of drugs that target this system. We performed proteomic analyses to investigate changes in protein abundance and posttranslational modifications in inhibitor-treated human KRAS-mutant pancreatic (KRAS G12C and G12D) and lung cancer (KRAS G12C) cells. The inhibitors used target these mutant forms of KRAS, the downstream effectors MEK and ERK, and the upstream regulators SHP2 and SOS1. Comparisons of phosphoproteomes between cell lines revealed a core KRAS signaling signature and cell line–specific signaling networks. In all cell lines, phosphoproteomes were dominated by different degrees of autonomous, oncogenic KRAS activity. Comparison of phosphoproteomes after short and long drug exposures revealed the temporal dynamics of KRAS-MEK-ERK axis inhibition that resulted in cell cycle exit. This transition to a quiescent state occurred in the absence of substantial proteome remodeling but included broad changes in protein phosphorylation and ubiquitylation. The collective data reveal insights into oncogenic KRAS signaling, place many additional proteins into this functional context, and implicate cell cycle exit as a mechanism by which cells evade death upon KRAS signaling inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)ProteomicsSignal TransductionLung NeoplasmsPancreatic NeoplasmsHumansCell Line, TumorProtein Tyrosine Phosphatase, Non-Receptor Type 11MutationMAP Kinase Signaling SystemSOS1 ProteinProteome

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11SOS1 ProteinPTPN11 protein, humanProteome

Autor:innen und Institutionen

  • School of Life Sciences, Technical University of Munich, Freising, Germany.
  • College of Health, Medicine and Life Science, Brunel University London, London, UK.
  • Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), School of Life Sciences, Technical University of Munich, Freising, Germany.
  • Department of Medicine III, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
  • TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.
  • OmicScouts GmbH, Freising, Germany.

ORCID-Profile: Nicole Kabella, Florian P Bayer, Konstantinos Stamatiou, Miriam Abele, Amirhossein Sakhteman, Yun-Chien Chang, Antje Gabriel, Johannes Krumm, Michael Aigner, Matthew The, Hannes Hahne, Florian Bassermann, Christina Ludwig, Paola Vagnarelli, Bernhard Kuster

Zitieren

APA

Kabella, N., Bayer, F. P., Stamatiou, K., Abele, M., Sakhteman, A., Chang, Y. C., Wagner, V., Gabriel, A., Krumm, J., Reinecke, M., Holzner, M., Aigner, M., The, M., Hahne, H., Bassermann, F., Ludwig, C., Vagnarelli, P., & Kuster, B. (2025). Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling. Science Signaling, 18(897). https://doi.org/10.1126/scisignal.adt6552

Vancouver

Kabella N, Bayer FP, Stamatiou K, Abele M, Sakhteman A, Chang YC, et al. Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling. Science Signaling. 2025;18(897). doi:10.1126/scisignal.adt6552

BibTeX
@article{Kabella2025,
  author = {Kabella, Nicole and Bayer, Florian P and Stamatiou, Konstantinos and Abele, Miriam and Sakhteman, Amirhossein and Chang, Yun-Chien and Wagner, Vinona and Gabriel, Antje and Krumm, Johannes and Reinecke, Maria and Holzner, Melanie and Aigner, Michael and The, Matthew and Hahne, Hannes and Bassermann, Florian and Ludwig, Christina and Vagnarelli, Paola and Kuster, Bernhard},
  title = {Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling},
  journal = {Science Signaling},
  year = {2025},
  volume = {18},
  number = {897},
  doi = {10.1126/scisignal.adt6552}
}
Kostenlos starten →